Listed

Airsculpt Technologies, Inc.: Form 10-Q for the period ended Sep 30, 2025

Filed with the SEC on Nov 7, 2025 and accepted by EDGAR at Nov 7, 2025, 16:37 ET.

Share

Management's discussion and analysis

As filed, 48,186 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes and other financial information appearing in our Annual Report on Form 10-K dated March 14, 2025 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”). This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including those risks. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report. You should read this Quarterly Report completely, including Part II, Item 1A (Risk Factors) of this Quarterly Report and the section titled “Cautionary Note Regarding Forward-Looking Statements” in this Quarterly Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by our forward-looking statements contained in the following discussion and analysis. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Unless otherwise indicated or the context otherwise requires, references in this Quarterly Report on Form 10-Q to the “Company,” “AirSculpt,” “we,” “us” and “our” refer to AirSculpt Technologies, Inc. and its consolidated subsidiaries and the professional associations.

Overview

AirSculpt is an experienced national provider of body contouring procedures delivering a premium consumer experience. We provide custom body contouring using our proprietary AirSculpt® method that removes unwanted fat and tightens skin in a minimally invasive procedure, producing dramatic results. We deliver our AirSculpt® procedures through a nationwide footprint of 31 centers across 20 states and Canada as of November 7, 2025.

For the three and nine months ended September 30, 2025, we performed 2,780 and 9,248 cases, respectively, compared to 3,277 and 10,972 for the three and nine months ended September 30, 2024, respectively. For the three and nine months ended September 30, 2025, we generated approximately $35.0 million and $118.4 million of revenue, respectively, compared to $42.5 million and $141.2 million for the three and nine months ended September 30, 2024, respectively. This represents approximately 18% decline in revenue for the three months ended September 30, 2025 over the same period in the prior year and approximately 16% decline in revenue for the nine months ended September 30, 2025 over the same period in the prior year.

In light of the decline in our revenue, we announced on March 14, 2025 an ongoing initiative to stabilize revenue growth through a number of strategic priorities, including:

  • optimizing our marketing investment by spending on techniques that have proven successful for us in the past using a returns-based approach and testing new areas such as online video, and other social marketing channels under the direction of our Chief Digital Officer;
  • improving our go-to-market and sales strategies under our Chief Sales Officer who is dedicated to strengthening our consultative sales model with enhanced training, improving our sales processes, and providing a greater focus on increasing lead generation, consultations, and case conversion;
  • enhancing our customer experience to ensure we consistently provide premium results, with initiatives that were launched during the quarter ended September 30, 2025 and that the Company expects to roll out into fiscal year 2026;
  • launching expanded consumer financing offerings across all of our centers in the first half of fiscal year 2025; and
  • focusing on new product innovation and introducing new services to expand our customer reach, leverage existing infrastructure and surgical expertise, and generate incremental revenues, including by expanding our pilot program of our skin tightening procedure as a standalone offering.

We have also implemented a cost reduction program that is estimated to eliminate approximately $3.0 million in annual overhead costs and contracted expenses, and have paused de novo center and new procedure room openings.

On September 1, 2025, we made the decision to close our facility in the United Kingdom because of its financial performance. Additionally, we estimate that we will cease use of our leased facility on November 15, 2025 and have adjusted the remaining right-of-use asset resulting in accelerated amortization of approximately $1.0 million of incremental rent expense in the quarter ended September 30, 2025. We expect to finalize the liquidation process in the fourth quarter of fiscal year 2025, and we do not anticipate any material future cash expenditures as a result of the planned closure.

As of September 30, 2025, we determined that it is no longer probable that a portion of our Salesforce software implementation project will be completed. As a result, we recorded an impairment charge of $4.6 million as of September 30, 2025 to adjust the software project to its fair value. We continue to develop the remaining portion of our software project and anticipate its completion in the first quarter of fiscal year 2026.

Key Operational and Business Metrics

In addition to the measures presented in our condensed consolidated financial statements, we use the following key operational and business metrics to evaluate our business, measure our performance, develop financial forecasts and make strategic decisions:

Cases Performed and Revenue per Case

Our case volumes in the table below, which are used for calculating revenue per case, represent one patient visit; notwithstanding that, a patient may have multiple areas treated during one visit. We believe this provides the best approach for assessing our revenue performance and trends.

Total Case and Revenue Metrics

Three Months Ended September 30, 2025 2024 Nine Months Ended September 30, 2025 2024
Cases 2,780 3,277 9,248 10,972
Case growth (15.2)% N/A (15.7)% N/A
Revenue per case $12,587 $12,984 $12,800 $12,867
Revenue per case growth (3.1)% N/A (0.5)% N/A
Number of facilities 32 31 32 31
Number of total procedure rooms 67 65 67 65

Same-Center Case and Revenue Metrics

Same-Center Information

For the three months ended September 30, 2025 and 2024, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the three months ended September 30, 2025 and 2024, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the three months ended September 30, 2025 in which such facilities were owned and operated during the three months ended September 30, 2024. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of September 30, 2024. Beginning September 30, 2025, we have excluded the London facility from all periods presented due to the closure of the facility.

For the nine months ended September 30, 2025 and 2024, we define same-center case and revenue growth as the growth in each of our cases and revenue at facilities that were owned and operated during the nine months ended September 30, 2025 and 2024, respectively. At facilities that were not owned or operated for the entirety of the prior year period, the current year period has been pro-rated to reflect only growth experienced during the portion of the nine months ended September 30, 2025 in which such facilities were owned and operated during the nine months ended September 30, 2024. We define same-center facilities and procedure rooms based on if a facility was owned or operated as of September 30, 2024. Beginning September 30, 2025, we have excluded the London facility from all periods presented due to the closure of the facility.

Three Months Ended September 30, 2025 2024 Nine Months Ended September 30, 2025 2024
Cases 2,580 3,244 8,436 10,882
Case growth (20.5)% N/A (22.5)% N/A
Revenue per case $12,574 $12,916 $12,777 $12,796
Revenue per case growth (2.6)% N/A (0.1)% N/A
Number of facilities 30 30 30 30
Number of total procedure rooms 63 63 63 63

Our same-center case decline is primarily attributed to weaker than expected performance across the broader aesthetics industry.

Non-GAAP Financial Measures—Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income per Share

We report our financial results in accordance with accounting principles generally accepted in the United States of America ("GAAP"), however, management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures.

We define Adjusted EBITDA as net loss excluding depreciation and amortization, net interest expense, income tax (benefit)/expense, restructuring and related severance costs, loss on impairment of long-lived assets, settlement costs for non-recurring litigation, and equity-based compensation.

We define Adjusted Net Income as net loss excluding restructuring and related severance costs, loss on impairment of long-lived assets, settlement costs for non-recurring litigation, equity-based compensation and the tax effect of these adjustments.

We include Adjusted EBITDA and Adjusted Net Income because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA and Adjusted Net Income each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not include results from equity-based compensation and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted Net Income has limitations as an analytical tool because it does not include results from equity-based compensation.

We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of revenue. We define Adjusted Net Income per Share as Adjusted Net Income divided by weighted average basic and diluted shares. We included Adjusted EBITDA Margin and Adjusted Net Income per Share because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin and Adjusted Net

Income per Share to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis.

The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net loss, the most directly comparable GAAP financial measure:

($ in thousands)

Three Months Ended September 30, 2025 2024 Nine Months Ended September 30, 2025 2024
Net loss $(9,512) $(6,040) $(12,950) $(3,217)
Plus
Equity-based compensation(1) 1,125 3,430 3,716 1,522
Restructuring and related severance costs 1,310 1,099 2,516 5,487
Depreciation and amortization 3,217 3,003 9,705 8,693
Loss on impairment of long-lived assets(2) 7,137 — 7,245 4
Litigation settlements(3) — 850 — 850
Interest expense, net 1,407 1,591 4,594 4,638
Income tax (benefit)/expense (1,645) 733 (2,197) 894
Adjusted EBITDA $3,039 $4,666 $12,629 $18,871
Adjusted EBITDA Margin 8.7% 11.0% 10.7% 13.4%

(1) During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of $10.4 million related to reassessing the probability of achieving the performance target on certain of the Company's performance-based stock units. See Note 6 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further discussion.

(2) During the third quarter of fiscal year 2025, the Company recorded a $4.6 million loss related to impairing a portion of the Salesforce implementation project and a $2.3 million loss related to the planned closure of the London facility and impairment of its fixed assets.See Note 1 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further discussion.

(3) This amount relates to settlement costs for non-recurring litigation of $0.9 million for the three and nine months ended September 30, 2024. See Note 9 to the condensed consolidated financial statements included in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 for further discussion.

20

The following table reconciles Adjusted Net (Loss)/Income and Adjusted Net (Loss)/Income per Share to net loss, the most directly comparable GAAP financial measure:

($ in thousands)

Three Months Ended September 30, 2025 2024 Nine Months Ended September 30, 2025 2024
Net loss $(9,512) $(6,040) $(12,950) $(3,217)
Plus
Equity-based compensation(1) 1,125 3,430 3,716 1,522
Restructuring and related severance costs 1,310 1,099 2,516 5,487
Loss on impairment of long-lived assets(2) 7,137 — 7,245 4
Litigation settlements(3) — 850 — 850
Tax effect of adjustments (2,462) (717) (2,850) 996
Adjusted net (loss)/income $(2,402) $(1,378) $(2,323) $5,642
Adjusted net (loss)/income per share of common stock (4)
Basic $(0.04) $(0.02) $(0.04) $0.10
Diluted $(0.04) $(0.02) $(0.04) $0.10
Weighted average shares outstanding
Basic 62,436,670 57,650,923 60,202,169 57,543,678
Diluted 62,436,670 57,650,923 60,202,169 58,289,022

(1) During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of $10.4 million related to reassessing the probability of achieving the performance target on certain of the Company's performance-based stock units. See Note 6 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further discussion.

(2) During the third quarter of fiscal year 2025, the Company recorded a $4.6 million loss related to impairing a portion of the Salesforce implementation project and a $2.3 million loss related to the planned closure of the London facility and impairment of its fixed assets.See Note 1 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further discussion.

(3) This amount relates to settlement costs for non-recurring litigation of $0.9 million for the three and nine months ended September 30, 2024. See Note 9 to the condensed consolidated financial statements included in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 for further discussion.

(4) Diluted Adjusted Net Income Per Share is computed by dividing adjusted net income by the weighted-average number of shares of common stock outstanding adjusted for the dilutive effect of all potential shares of common stock.

Components of Results of Operations

Revenue

Our revenue is generated from our patented AirSculpt® procedures performed on our patients. We are 100% self-pay and do not accept payments from the U.S. federal government or payer organizations. We assist patients, as needed, by providing third-party financing options to pay for procedures. We have arrangements with various financing companies to facilitate this option. There is a financing transaction fee based on a set percentage of the amount financed. We recognize revenue based on the expected transaction price which is reduced for financing fees.

Our policy is to require full payment for services in advance of performing a procedure. Payments received for which services have yet to been performed for all reported periods are included in deferred revenue and patient deposits on our balance sheets.

Cost of Service (excluding depreciation and amortization)

Cost of service is comprised of all service and product costs related to the delivery of procedures, including but not limited to compensation to our physicians and clinical staff, medical supply costs, and facility-related rent expense.

Operating Expense

Selling, General and Administrative

Selling, general and administrative consists of marketing and advertising expenses we incur to market our patented AirSculpt® procedures to potential patients and general and administrative costs, including rent for our corporate offices.

Selling Expenses

Selling expenses consist of advertising costs for social, digital and traditional marketing and sales and marketing personnel. Our advertising costs include both national and site-based advertising used to generate greater awareness and engagement among our current and potential patients. Our advertising costs include social media, digital marketing and traditional advertising. Selling expenses include salaries and commissions for employees engaged in marketing and sales. We define our customer acquisition costs as the total selling expenses per case.

We evaluate our selling expense as compared to growth in our sales volume and will invest accordingly to the extent we believe we can position ourselves for future growth without materially negatively impacting our Adjusted EBITDA Margins.

General and Administrative

General and administrative expenses include employee-related expenses, including salaries and related costs (excluding physician and clinical cost included in cost of service and the salaries and commissions of sales and marketing employees), equity-based compensation, technology, operations, finance, legal, corporate office rent and human resources.

Interest Expense

Interest expense, net consists primarily of interest costs on our outstanding borrowings under our debt.

Results of Operations

Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

The following table and notes summarize certain results from the statements of operations for each of the periods indicated and the changes between periods. The table also shows the percentage relationship to revenue for the periods indicated:

($ in 000s) Three Months Ended September 30, 2025 Amount % of Revenue 2024 Amount % of Revenue
Revenue $34,993 100.0% $42,548 100.0%
Operating expenses:
Cost of service 14,864 42.5% 17,766 41.8%
Selling, general and administrative 19,525 55.8% 25,495 59.9%
Depreciation and amortization 3,217 9.2% 3,003 7.1%
Loss on impairment of long-lived assets 7,137 20.4% — —%
Total operating expenses 44,743 127.9% 46,264 108.7%
Loss from operations (9,750) (27.9)% (3,716) (8.7)%
Interest expense, net 1,407 4.0% 1,591 3.7%
Pre-tax net loss (11,157) (31.9)% (5,307) (12.5)%
Income tax benefit (1,645) (4.7)% 733 1.7%
Net loss $(9,512) (27.2)% $(6,040) (14.2)%

Revenue— Our revenue decreased $7.6 million, or 17.8%, compared to the same period in 2024. The decrease is primarily attributed to weaker than expected performance across the broader aesthetics industry.

Cost of Service— Our cost of services decreased $2.9 million, or 16.3%, compared to the same period in 2024. The percentage decrease in cost of service is driven by the decrease in cases compared to the same period in 2024. Cost of service was 42.5% and 41.8% as a percentage of revenue for the three months ended September 30, 2025 and 2024, respectively. This is primarily due to not being able to leverage certain fixed costs within cost of service like rent and certain nursing costs.

Selling, General and Administrative Expenses— Selling, general and administrative expenses decreased $6.0 million, or 23.4%, for the three months ended September 30, 2025 compared to the same period in 2024. This decrease relates to a $0.5 million reduction in advertising costs, $2.3 million decrease in stock compensation expense, $1.4 million reduction in legal and professional service costs, $0.6 million reduction in travel, as well as a $0.8 million reduction in legal settlement costs, offset by a $1.1 million increase in rent expense related to the accelerated amortization of the London facility right-of-use assets. Selling, general and administrative expenses as a percent of revenue was at 55.8% and 59.9% for the three months ended September 30, 2025 and 2024, respectively.

Selling expenses consist of advertising costs for social, digital and traditional marketing and sales and marketing personnel. Total selling expenses were approximately $8.8 million and $9.6 million for the three months ended September 30, 2025 and 2024, respectively. This decrease is primarily related to a decrease in advertising spend associated with brand awareness initiatives. Our customer acquisition costs were approximately $3,145 and $2,900 per customer in the three months ended September 30, 2025 and 2024, respectively. Selling expenses as a percentage of revenue may fluctuate from quarter to quarter based on the timing and scope of our initiatives and the related impact to our revenue. We have also paused de novo center and new procedure room openings, which is expected to have a favorable impact on selling expenses.

General and administrative expenses include employee-related expenses, including salaries and related costs (excluding physician and clinical cost included in cost of service), equity-based compensation, technology, operations, finance, legal, corporate office rent and human resources. General and administrative expenses were approximately $10.8 million and $15.9 million for the three months ended September 30, 2025 and 2024, respectively. This decrease relates to a $2.3 million decrease in stock compensation expense and $1.4 million decrease in legal and professional service costs. We have also implemented a cost reduction program that was estimated to eliminate approximately $3.0 million in annual overhead costs and contracted expenses during fiscal year 2025.

Depreciation and Amortization— Depreciation and amortization increased to approximately $3.2 million for the three months ended September 30, 2025 compared to $3.0 million for the same period in 2024. This increase is the result of having five additional de novo centers during the three months ended September 30, 2025 as compared to the 2024 period.

Loss on impairment of long-lived assets— The $7.1 million loss on impairment of long-lived assets during the three months ended September 30, 2025 relates to the $4.6 million impairment of portions of the Company's Salesforce implementation project as well as the $2.3 million impairment of property, plant, and equipment related to the London facility as a result of its planned closure.

Interest Expense, net— Interest expense was $1.4 million and $1.6 million for the three months ended September 30, 2025 and 2024, respectively.

Income Tax Expense— Our effective tax rate was 14.7% and (13.8)% for the three months ended September 30, 2025 and 2024, respectively. The main driver of the difference between the effective and statutory rate is non-deductible executive compensation under Section 162(m) of the Internal Revenue Code.

Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024

The following table and notes summarize certain results from the statements of operations for each of the periods indicated and the changes between periods. The table also shows the percentage relationship to revenue for the periods indicated:

($ in 000s) Nine Months Ended September 30, 2025 Amount % of Revenue 2024 Amount % of Revenue
Revenue $118,376 100.0% $141,172 100.0%
Operating expenses:
Cost of service 48,015 40.6% 54,635 38.7%
Selling, general and administrative 63,964 54.0% 75,525 53.5%
Depreciation and amortization 9,705 8.2% 8,693 6.2%
Loss on impairment of long-lived assets 7,245 6.1% 4 —%
Total operating expenses 128,929 108.9% 138,857 98.4%
(Loss)/income from operations (10,553) (8.9)% 2,315 1.6%
Interest expense, net 4,594 3.9% 4,638 3.3%
Pre-tax net (loss)/income (15,147) (12.8)% (2,323) (1.6)%
Income tax (benefit)/expense (2,197) (1.9)% 894 0.6%
Net (loss)/income $(12,950) (10.9)% $(3,217) (2.3)%

*Revenue—*Our revenue decreased $22.8 million, or 16.1%, compared to the same period in 2024. The decrease is primarily attributed to weaker than expected performance across the broader aesthetics and high-end retail industries.

*Cost of Service—*Our cost of service decreased $6.6 million, or 12.1%, compared to the nine months ended September 30, 2024. The percentage decrease in cost of service is driven by the decrease in cases compared to the same period in 2024. Cost of service was 40.6% and 38.7% as a percentage of revenue for the twelve months ended September 30, 2025 and 2024, respectively. The percentage increase is primarily due to the decline in revenue and not being able to leverage certain fixed costs within cost of service such as rent and certain nursing costs.

*Selling, General and Administrative Expenses—*Selling, general and administrative expenses decreased $11.6 million, or 15.3%, for the nine months ended September 30, 2025 compared to the same period in 2024. This decrease relates to a $5.4 million reduction in advertising costs, $3.7 million decrease in severance expense, $1.6 million reduction in legal and professional service costs, $1.0 million reduction in travel, as well as a $1.0 million reduction in legal settlement costs, offset by a $1.0 million increase in rent expense related to the accelerated amortization of the London facility right-of-use asset. Selling, general and administrative expenses as a percent of revenue were 54.0% and 53.5% for the nine months ended September 30, 2025 and 2024, respectively.

Selling expenses consist of advertising costs for social, digital and traditional marketing and sales and marketing personnel. Total selling expenses were approximately $28.2 million and $34.0 million for the nine months ended September 30, 2025 and 2024, respectively. This decrease is primarily related to a decrease in advertising spend associated with brand awareness initiatives. Our customer acquisition costs were approximately $3,050 and $3,095 per customer in the nine months ended September 30, 2025 and 2024, respectively. Additionally, selling expenses as a percentage of revenue may fluctuate from quarter to quarter based on the timing and scope of our initiatives and the related impact to our revenue. We have also paused de novo center and new procedure room openings, which is expected to have a favorable impact on selling expenses.

General and administrative expenses include employee-related expenses, including salaries and related costs (excluding physician and clinical cost included in cost of service), equity-based compensation, technology, operations, finance, legal, corporate office rent and human resources. General and administrative expense were approximately $35.7 million and $41.5 million for the nine months ended September 30, 2025 and 2024, respectively. This decrease relates to reductions in severance, legal and professional service costs, legal settlement costs, and travel, offset by a $1.0 million increase in rent expense related to the accelerated amortization of the London facility right-of-use asset. Many of these improvements are the result of a cost reduction program that was estimated to eliminate approximately $3.0 million in annual overhead costs and contracted expenses during fiscal year 2025.

*Depreciation and Amortization—*Depreciation and amortization increased to approximately $9.7 million for the nine months ended September 30, 2025 compared to $8.7 million for the same period in 2024. This increase is the result of having five additional de novo centers during the nine months ended September 30, 2025 as compared to the 2024 period.

Loss on impairment of long-lived assets— The $7.2 million loss on impairment of long-lived assets during the nine months ended September 30, 2025 primarily relates to the $4.6 million impairment of portions of the Company's Salesforce implementation project as well as the $2.3 million write-off of property, plant, and equipment related to the London facility as a result of its planned closure.

*Interest Expense, net—*Interest expense increased to $4.6 million from $4.6 million for the nine months ended September 30, 2025 and 2024, respectively.

Income Tax Expense— Our effective tax rate was 14.5% and (38.5)% for the nine months ended September 30, 2025 and 2024, respectively. The main driver of the difference between the effective and statutory rate is non-deductible executive compensation under Section 162(m) of the Internal Revenue Code.

Liquidity and Capital Resources

We principally rely on cash flows from operations as our primary source of liquidity and, if needed, up to $5.0 million in revolving loans under our revolving credit facility, subject to minimum liquidity draw requirements. In March 2025, we filed a Registration Statement on Form S-3 (File No. 333-285825) which covers the offering, issuance and sale, for an aggregate initial offering price not to exceed $100.0 million, of shares of common stock and preferred stock; debt securities; warrants to purchase common stock, preferred stock and/or debt securities; and units. We also commenced an at-the-market offering program, with Leerink Partners LLC (“Leerink”) acting as sales agent. This at-the-market offering program provides us with additional access to capital, as needed, subject to market conditions.

Our primary cash needs are for payroll, marketing and advertisements, rent, debt service, as well as information technology and infrastructure, including our corporate office. Our cash flows are closely tied to the receipt of patient payments, and we have experienced revenue declines in the most recent year due to a decline in overall cases performed. In response, we have implemented initiatives to improve revenue growth, engaged in a cost reduction program that was estimated to eliminate approximately $3.0 million in annual overhead costs and contracted expenses during fiscal year 2025, and paused de novo center and new procedure room openings. These initiatives may not realize anticipated benefits or savings from one or more of the various strategies and cost-savings initiatives undertaken as part of these efforts in full or in part or within the time periods expected. We also may not realize the increase in sales related to these initiatives. Our ability to improve operating results depends upon a significant number of factors, some of which are beyond our control. If we are unable to realize the anticipated savings or benefits, or otherwise fail to implement the growth strategies, the business operating results and liquidity may be adversely affected.

We believe that the cash expected to be generated from operations will be sufficient for our working capital requirements, liquidity obligations, and payments due under our existing credit facilities for at least the next 12 months.

As of September 30, 2025, we had $5.4 million in cash and cash equivalents and an available amount of $5.0 million under our revolving credit facility. We did not have any letters of credit outstanding as of September 30, 2025.

As of September 30, 2024, we had $6.0 million in cash and cash equivalents and an available amount of $5.0 million under our revolving credit facility. We did not have any letters of credit outstanding as of September 30, 2024.

The following table summarizes the net cash provided by (used for) operating activities, investing activities and financing activities for the periods indicated:

($ in 000s) Cash Flows Provided By (Used For): Nine Months Ended September 30, 2025 2024
Operating activities $5,627 $8,637
Investing activities (2,346) (10,479)
Financing activities (6,111) (2,448)
Net decrease in cash and cash equivalents (2,830) (4,290)

Operating Activities

The primary source of our operating cash flow is the collection of patient payments received prior to performing surgical procedures. For the nine months ended September 30, 2025, our operating cash flow decreased by $3.0 million compared to the same period in 2024. The decrease is primarily attributed to weaker than expected revenue performance during the nine months ended September 30, 2025 as compared to the prior year period. At September 30, 2025, we had a working capital deficit of $(11.9) million compared to $(11.5) million at December 31, 2024.

Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2025 and 2024 was $2.3 million and $10.5 million, respectively. Investing activities in the nine months ended September 30, 2025 relate primarily to final payments on our White Plains, NY location that opened in December 2024 and maintenance capital expenditure. Investing activities during the nine months ended September 30, 2024 were attributable to the preparation for the opening of our 2024 de novo locations.

Financing Activities

Net cash used in financing activities during the nine months ended September 30, 2025 was $6.1 million. During the nine months ended September 30, 2025, we received net proceeds of $14.0 million from an underwritten public offering, made principal payments on our debt of $12.9 million, payments for debt modification of $0.3 million and made payments of taxes withheld through vested equity-based compensation of $0.1 million.

Net cash used in financing activities for the nine months ended September 30, 2024 was $2.4 million. For the nine months ended September 30, 2024, we made principal payments on our debt of $1.6 million and made payments of taxes withheld through vested equity-based compensation of $0.5 million.

At-the-Market Common Offering Program

On March 14, 2025, we entered into a sales agreement (the “ATM Agreement”) with Leerink, as sales agent, in connection with an at-the-market offering program under which we may offer and sell, from time to time in our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0 million at prices and on terms to be determined by market conditions at the time of offering. The $50.0 million of common stock that may be offered, issued and sold under the ATM Agreement is included in the $100.0 million of securities that may be offered, issued and sold by us under our Registration Statement on Form S-3 (File No. 333-285825). We and Leerink each have the right to suspend or terminate the ATM Agreement in each party’s sole discretion at any time.

During the three and nine months ended September 30, 2025, we sold the following quantities of our common stock pursuant to the ATM Agreement for total net proceeds of approximately $0 and $264 thousand:

Date Shares
3/26/2025 4,486
3/27/2025 1,132
Q1 Total 5,618
4/1/2025 51,513
4/2/2025 67,069
Q2 Total 118,582
Q3 Total —

2025 Underwritten Follow-On Equity Offering

On June 9, 2025, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC (“Leerink Partners”), to issue and sell 3,160,000 shares (the “Firm Shares”) of the Company’s common stock to Leerink Partners, in an underwritten registered public offering (the “Offering”), at a price of $3.80 per share. Pursuant to the Underwriting Agreement, the Company also granted Leerink Partners a 30-day option to purchase up to an additional 474,000 shares of the Company's common stock (the “Additional Shares,” and together with the Firm Shares, the “Shares”), at the same price per share as the Firm Shares. Leerink Partners exercised in full its option to purchase the Additional Shares on June 10, 2025. Vesey Street Capital Partners, L.L.C., which is affiliated with two directors and is the largest stockholder of the Company, purchased an aggregate of 1,000,000 Shares in the Offering on the same terms and conditions as purchases by the public in the Offering.

The Offering closed on June 11, 2025, and the Company received net proceeds of approximately $13.8 million from the sale of 3,634,000 Shares, which included the 474,000 Additional Shares, after deducting estimated offering expenses. The Company used the net proceeds from the Offering for the prepayment of a portion of the Company’s outstanding indebtedness under its existing credit agreement and the remainder of the net proceeds from the Offering for general corporate purposes, including working capital and other business opportunities.

The Offering was pursuant to a prospectus supplement dated June 9, 2025, filed with the SEC in connection with the Company’s shelf registration statement on Form S-3 (File 333-285825), filed with the SEC on March 14, 2025 and declared effective on March 24, 2025 and the related prospectus dated March 14, 2025.

Long-Term Debt

The carrying value of our total indebtedness was $56.9 million and $74.7 million, which includes unamortized deferred financing costs and issuance discount of $1.0 million and $1.0 million, and funds drawn on the revolving credit facility of $0.0 million and $5.0 million, as of September 30, 2025 and December 31, 2024, respectively.

On November 7, 2022, the Company entered into a credit agreement with a syndicate of lenders (the "Credit Agreement"), originally maturing November 7, 2027. Pursuant to the Credit Agreement, there is (i) an $85.0 million original aggregate principal amount of term loans and (ii) a revolving loan facility in an aggregate principal amount of up to $5.0 million. On September 29, 2023, the Company voluntarily pre-paid $10.0 million of the principal balance of the term loans under the Credit Agreement using cash on hand.

Under the Credit Agreement, all outstanding loans bear interest based on either a base rate or SOFR plus an applicable per annum margin. The applicable per annum margin is 2.0% or 3.0% for base rate or SOFR, respectively, if the Company's total leverage ratio is equal to or greater than 2.0x. If the Company's total leverage ratio is equal to or greater than 1.0x and less than 2.0x, the applicable per annum margin is 1.5% or 2.5% for base rate or SOFR, respectively. If the Company's total leverage ratio is below 1.0x, the applicable per annum margin is 1.0% or 2.0% for base rate or SOFR, respectively.

On September 13, 2024, the Company amended the Credit Agreement to modify certain financial condition covenants and the applicable margins. As such, for the period of September 13, 2024 through June 30, 2025, the applicable per annum margin was 2.5% or 3.5% for base rate or SOFR, respectively, if the Company's total leverage ratio was equal to or greater than 2.0x. If the Company's total leverage ratio was equal to or greater than 1.0x and less than 2.0x, the applicable per annum margin was 2.0% or 3.0% for base rate or SOFR, respectively. If the Company's total leverage ratio was below 1.0x, the applicable per annum margin was 1.5% or 2.5% for base rate or SOFR, respectively.

On March 12, 2025, the Company entered into the Third Amendment to the Credit Agreement (the "Third Amendment"). Under the terms of the Third Amendment, the parties thereto agreed to modify certain financial condition covenants made by the Company under the term loan and revolving credit facility, such that (i) the Consolidated Fixed Charge Coverage Ratio (as defined in the Credit Agreement) of the Company and its subsidiaries as of the last day of the fiscal quarters ending March 31, 2025 and June 30, 2025 must be no less than 0.50x and 1.10x, respectively, and no less than 1.25x on the last day of the fiscal quarters ending September 30, 2025 and thereafter, instead of 1.10x as of March 31, 2025 and 1.25x as of June 30, 2025 and thereafter, as previously set forth in the Credit Agreement; (ii) the Consolidated Leverage Ratio (as defined in the Credit Agreement) of the Company and its subsidiaries as of the last day of the fiscal quarters ending March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025 and March 31, 2026, must not exceed 4.25x, 3.50x 3.25x, 3.25x, and 2.75x, respectively, and the Consolidated Leverage Ratio as of the last day of each fiscal quarter thereafter must not exceed 2.25x, instead of 3.25x as of March 31, 2025, 2.75x as of June 30, 2025, and 2.25x thereafter, as previously set forth in the Credit Agreement; (iii) the Company and its subsidiaries will be required to maintain minimum Liquidity (as defined in the Credit Agreement) of not less than (A) $3.0 million as of the last day of the month ending March 31, 2025, (B) $5.0 million as of the last day of the month ending April 30, 2025, and (C) $7.5 million as of the last day of the months ending May 31, 2025 and thereafter (or the last day of each fiscal quarter thereafter upon the satisfaction of certain financial tests described therein); and (iv) new liquidity and financial reporting requirements have been added.

In addition to revising the covenants listed above, the Third Amendment revised or added new terms such that (i) for outstanding loans, beginning on or about July 1, 2025, the applicable per annum margin will be increased to 3.75% or 4.75% for base rate or SOFR, respectively, if the Company's total leverage ratio is equal to or greater than 3.00x, 3.50% or 4.50% for base rate or SOFR, respectively, if the Company's total leverage ratio is equal to or greater than 2.00x and less than 3.00x, and 3.25% or 4.25% for base rate or SOFR, respectively, if the Company's total leverage ratio is below 2.00x, (ii) the term loan and revolving credit facility will mature on May 11, 2027 (instead of November 7, 2027); (iii) Liquidity in excess of $3.0 million will be used to repay the outstanding funds drawn on the revolving credit facility on a monthly basis beginning April 30, 2025; (iv) revolver draws will be subject to compliance with the minimum Liquidity covenant; (v) the Company will be required to reimburse SVB for certain fees and expenses relating to the engagement of a financial advisor, and (vi) 100% of first $10.0 million of any equity proceeds will be used to repay the term loan and revolving credit facility, subject to a carve-out of the first $3.0 million of equity proceeds and any equity proceeds received from Vesey Street Capital Partners, L.L.C., our private equity sponsor (“Sponsor”). In consideration of the Third Amendment, the Company paid a fee equal to 0.15% of the outstanding loans to consenting Lenders, and a $125 thousand arrangement fee to Silicon Valley Bank. On March 12, 2025, in connection with the Third Amendment, the Company, SVB and our Sponsor (through certain affiliated entities) entered into that certain Limited Guarantee by and among Vesey Street Capital Partners Healthcare Fund, L.P., Vesey Street Capital Partners Healthcare Fund-A, L.P., SVB, and the Company (the "Limited Guarantee"), pursuant to which our Sponsor agreed to provide a $10.0 million limited guaranty of the Company’s obligations under the Credit Agreement. The Limited Guarantee was callable on June 15, 2025 (or upon the earlier occurrence of certain defaults described therein) if the Company had not prepaid the term loan (excluding regularly scheduled amortization) by $10.0 million as of such date. Under the terms of the Limited Guarantee, if our Sponsor was required to make any payment under the Limited Guarantee (other than as a result of a bankruptcy event), then our Sponsor would be deemed to have purchased shares of common stock of the Company having an aggregate value equal to the amount of such payment. The Company agreed to issue a subordinated note to our Sponsor if a payment occurred under the Limited Guarantee, to the extent such payment did not result from the issuance of shares of common stock by the Company to our Sponsor.

On June 13, 2025, the Company made a $10.0 million principal payment on the term loan in accordance with the Third Amendment using proceeds from its underwritten public offering completed on June 11, 2025.

As of September 30, 2025, the interest rate under the Credit Agreement was 8.82%.

JOBS Act Accounting Election

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our IPO or until we are no longer an “emerging growth company,” whichever is earlier.

Critical Accounting Policies and Estimates

A summary of significant accounting policies is disclosed in our Annual Report on Form 10-K dated March 14, 2025 filed with the SEC pursuant to Section 13 or 15d of the Exchange Act under the caption “Critical Accounting Policies and Estimates” in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section. There have been no material changes in the nature of our critical accounting policies and estimates or the application of those policies from our Annual Report on Form 10-K dated March 14, 2025.

Market risk

As filed, 160 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required under this item.

Controls and procedures

As filed, 3,020 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Management’s Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required financial disclosure.

As of the end of the period covered by this Quarterly Report on Form 10-Q, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(e) and 15d-15(e). Based upon this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2025.

Changes in Internal Controls Over Financial Reporting

During the quarter ended September 30, 2025, we adjusted personnel responsibility for our internal control over financial reporting to address the departure of our former Chief Accounting Officer. There were no other changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the quarter ended September 30, 2025.

Limitations on the Effectiveness of Controls

Our management, including the Chief Executive Officer and the Chief Financial Officer, recognizes that any set of controls and procedures, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision- making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. For these reasons, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Risk factors

As filed, 560 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Except to the extent updated below or to the extent additional factual information disclosed elsewhere in this Quarterly Report on Form 10-Q relates to such risk factors (including, without limitation, the matters discussed in Part I, “Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations”), there were no material changes to the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2024 dated March 14, 2025 and filed with the SEC pursuant to Section 13 or 15(d) of the Exchange Act.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-07-01 to 2025-09-30$35.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2025-01-01 to 2025-09-30$118.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Selling, general and administrative3 months2025-07-01 to 2025-09-30$19.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2025-01-01 to 2025-09-30$64.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-07-01 to 2025-09-30−$9.8mus-gaap:OperatingIncomeLoss
Operating income9 months2025-01-01 to 2025-09-30−$10.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-07-01 to 2025-09-30$1.4mus-gaap:InterestExpenseNonoperating
Interest expense9 months2025-01-01 to 2025-09-30$4.6mus-gaap:InterestExpenseNonoperating
Income tax3 months2025-07-01 to 2025-09-30−$1.6mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2025-01-01 to 2025-09-30−$2.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-07-01 to 2025-09-30−$9.5mus-gaap:NetIncomeLoss
Net income9 months2025-01-01 to 2025-09-30−$12.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-07-01 to 2025-09-30−$0.15us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2025-01-01 to 2025-09-30−$0.22us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-07-01 to 2025-09-30−$0.15us-gaap:EarningsPerShareBasic
Basic EPS9 months2025-01-01 to 2025-09-30−$0.22us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-07-01 to 2025-09-3062,436,670 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2025-01-01 to 2025-09-3060,202,169 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2025-01-01 to 2025-09-30$5.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2025-01-01 to 2025-09-30$2.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2025-07-01 to 2025-09-30$0us-gaap:PaymentsOfDividends
Dividends paid9 months2025-01-01 to 2025-09-30$0us-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2025-09-30$5.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-09-30$12.2mus-gaap:AssetsCurrent
Total assetsAt period end2025-09-30$185.9mus-gaap:Assets
Current liabilitiesAt period end2025-09-30$24.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-09-30$103.8mus-gaap:Liabilities
Long-term debtAt period end2025-09-30$51.9mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2025-09-30$5.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2025-09-30$82.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001870940-25-000040. Last ingested by Listed: Nov 13, 2026, 16:33 ET. Listed shows no prices and gives no investment advice.